LOGIN  |  REGISTER
Chimerix
Chimerix

Mettler-Toledo Announces Webcast of Presentation at the Jefferies Healthcare Conference

May 25, 2023 | Last Trade: US$1,331.29 4.55 -0.34

Columbus, OH, May 25, 2023 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 8:30 a.m Eastern Time.  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.investors.mt.com.  A replay of the webcast will be available.

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.    

Assertio

Stock Quote

Last Trade: US$1,331.29
Daily Change: -4.55 -0.34
Daily Volume: 74,765
Market Cap: US$28.480B

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB